

Table S1 Baseline characteristics of patients with lung adenosquamous carcinoma received ICI monotherapy and combination ICI therapy

Characteristics	Patients, n (%)	Monotherapy, n (%)	Combination treatment, n (%)	P value
ECOG PS				
0-1	31 (81.6)	8 (88.9)	23 (79.3)	1.000
2	7 (18.4)	1 (11.1)	6 (20.7)	
TNM staging				
III	9 (23.7)	2 (22.2)	7 (24.1)	1.000
IV	29 (76.3)	7 (77.8)	22 (75.9)	
Liver metastasis				
Yes	4 (10.5)	0 (0)	4 (13.8)	0.554
No	34 (89.5)	9 (100.0)	25 (96.2)	
Brain metastasis				
Yes	7 (18.4)	1 (11.1)	6 (20.7)	1.000
No	31 (81.6)	8 (88.9)	23 (79.3)	
Bone metastasis				
Yes	14 (36.8)	4 (44.4)	10 (34.5)	0.699
No	24 (63.2)	5 (55.6)	19 (65.5)	
PD -L1 status				
Positive	11 (28.9)	3 (33.3)	8 (27.6)	1.000
Negative	6 (15.8)	1 (11.1)	5 (17.2)	
Unknown	21 (55.3)	5 (55.6)	16 (55.2)	
PD-1 inhibitors				
Sintilimab	13 (34.2)	1 (11.1)	12 (41.4)	0.283
Tislelizumab	5 (13.2)	1 (11.1)	4 (13.8)	
Pembrolizumab	6 (15.8)	1 (11.1)	5 (17.2)	
Nivolumab	4 (10.5)	2 (22.2)	2 (6.9)	
Other PD-1 inhibitors	10 (26.3)	4 (44.4)	6 (20.7)	
Line of ICI treatment				
First line	17 (44.7)	2 (22.2)	15 (51.7)	0.148
Second or more line	21 (55.3)	7 (77.8)	21 (72.4)	
ICI combination drugs				
Taxane plus platinum	12 (41.4)	0 (0.0)	12 (41.4)	< 0.001
Pemetrexed plus platinum	6 (20.7)	0 (0.0)	6 (20.7)	
Pemetrexed	5 (17.2)	0 (0.0)	5 (17.2)	
Taxane	3 (10.3)	0 (0.0)	3 (10.3)	
Taxane plus bevacizumab	3 (10.3)	0 (0.0)	3 (10.3)	

ECOG PS, Eastern Cooperative Oncology Group Performance status; ICI, immune checkpoint inhibitor; PD-L1, programmed death-ligand 1.